$RMAX

Real-REMAX Deal Clears DOJ and FTC Scrutiny

Real’s SEC filing says the DOJ granted early termination of the antitrust waiting period for Real’s $880 million bid to buy RE/MAX. The FTC says early termination occurs only after both agencies complete review and plan no enforcement during the period. Shareholder approval is set for Aug. 14. Real shares rose about 4% after the filing.

Original reporting
Published Jul 14, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 7:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMergers & acquisitions
Primary signal
$RMAX
Bullish
medium confidence
Mentioned
$RMAX
Relevance
8/10
alphai data visualization · based on rismedia.com
Decision brief

The 30-second read

$RMAXBullishMed
01

Why it matters

DOJ early termination of the mandatory waiting period is a concrete regulatory milestone that reduces antitrust timing risk, but the deal still depends on FTC review and shareholder approval scheduled for Aug. 14.

02

Market read

Regulatory progress on a major brokerage M&A deal can reprice closing probability and near-term deal-spread risk for both acquirer and target.

03

What to watch

Shareholder approval timing and any FTC enforcement action, plus New York’s investigation, are still unresolved and could dominate price action after the initial regulatory headline.

Relevance 8/10Novelty 7/10Timing: ahead of the Aug. 14 shareholder vote, after DOJ early termination filing

Background

The article frames the Real-REMAX deal as part of broader real estate brokerage consolidation and contrasts it with other deals that reportedly faced more scrutiny.

Company-level read

Ticker impact

$RMAXBullishMedium confidence
Context

Real’s SEC filing says DOJ granted early termination for its $880M bid to purchase REMAX, moving the antitrust review forward.

Expected impact

Near-term upside bias on deal-close odds; further moves likely hinge on FTC and shareholder approval.

Evidence & confidence

The article cites a specific DOJ procedural step (early termination) that typically lowers the likelihood of an extended antitrust process, but FTC review and shareholder voting remain outstanding.

Market effects

Signals continued consolidation momentum in real estate brokerage, with antitrust review timelines potentially shortening under certain administrations.

New York’s state-level investigation adds a parallel regulatory overhang that could affect deal timing or remedies.

Limited direct global impact, but it reinforces how US antitrust process mechanics can shape M&A execution risk.

Counterpoint

DOJ early termination does not eliminate FTC or state challenges; the market may be underpricing the risk of remedies or delays.

Key entities

  • Real

    Acquirer in the proposed $880M purchase of REMAX; filed with the SEC that DOJ granted early termination.

  • REMAX

    Target in the proposed acquisition; deal requires shareholder approval and remains subject to ongoing antitrust review.

  • Department of Justice (DOJ)

    Granted early termination of the mandatory waiting period for the merger.

  • Federal Trade Commission (FTC)

    Indicated early termination occurs only when both DOJ and FTC have completed review without enforcement action during the waiting period.

  • New York

    Launched a state-level investigation into the merger.

Related articles

$RMAXMed

RE/MAX (NYSE:RMAX) Misses Q2 CY2026 Sales Expectations

RE/MAX (NYSE:RMAX) reported Q2 CY2026 results that missed Wall Street expectations. Revenue fell 5.8% year on year to $68.51 million, and non-GAAP adjusted EPS was $0.32, down from $0.39 and 18.6% below consensus. Analysts expect revenue to rise 3.3% and full-year EPS to increase from $1.15 to $1.33.

$RMAXMedAI 8/10

RE/MAX HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS

RE/MAX Holdings (NYSE: RMAX) reported Q2 2026 revenue of $68.5M, down 5.8% year over year, and adjusted EBITDA of $22.9M, down 12.6%. GAAP net loss was $4.3M, or -$0.20 per diluted share. The company also disclosed a planned merger with The Real Brokerage, offering Real REMAX Group shares or $13.80 cash per RMAX share, expected to close in H2 2026.

$RMAXMed

RE/MAX Holdings, Inc. (RMAX): Results of Operations and Financial Condition

RE/MAX Holdings, Inc. (RMAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622438d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RE/MAX HOLDINGS, INC. REPORTS SECOND QUARTER 2026 RESULTS Total Second Quarter Revenue of $68.5 Million, Adjusted EBITDA of $22.9 Million DENVER, August 6, 2026 Second Quarter 2026 Highlights (Compared to second quarter 2

$RMAXMedAI 8/10

Why RE/MAX (RMAX) Stock Is Up Today

RE/MAX (RMAX) shares rose after the DOJ granted early termination of the HSR waiting period for its proposed merger with The Real Brokerage, removing a key antitrust review hurdle. The deal still requires shareholder approvals. RMAX closed at $10.71, up 0.9% on the day.

$RKLBMedAI 8/10

Rocket Lab (RKLB) Won a Major Space Force Contract. Now It Has to Prove Neutron

Rocket Lab (NASDAQ:RKLB) said Aug. 4 it won a $397 million U.S. Space Force contract under the SB-AMTI program to develop, launch and operate Flatellite satellites for airborne target tracking. The work depends on Rocket Lab’s Neutron rocket, whose first flight has been delayed to late 2026 after a Stage 1 tank failure. Rocket Lab reported Q1 FY2026 revenue of $200.3 million.

$DVHighAI 9/10

DoubleVerify Shares Rally After Nielsen Agrees to $2.15 Billion Takeover

DoubleVerify (NYSE:DV) shares rose about 13.6% premarket after Nielsen Holdings agreed to buy DV in an all-cash deal valued at about $2.15 billion. DV shareholders will receive $13.60 per share, a 30% premium to the 60-day VWAP. The boards approved; closing is expected in Q1 2027. Several brokerages cut ratings to Hold/Market Perform with targets at $13.60.